A protocol for transitioning patients with heart failure and a left ventricular assist device to a stepdown unit from the ICU ...

Affecting 1 in 500 people, hypertrophic cardiomyopathy is a condition in which the walls of the left ventricle, the heart's main pumping chamber, become abnormally thick. "HCM is one of the primary ...

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in ...

Hypertrophic cardiomyopathy, also known as HCM or thick heart syndrome, is a genetic condition that causes your heart muscle ...

Oncology nurses play essential roles in the emerging field of cardio-oncology, which aims to protect patients’ heart function ...

One halcyon spring day in 1903, the 69-year-old anatomist and naturalist Dr. James Bell Pettigrew sat at the top of a sloping ...

Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...

Their son had an atrial septal defect, a ventricular septal defect, tricuspid atresia and a hypoplastic right ventricle. In ...

Patients and families need to know how these extraordinary treatments might change how they feel about themselves and the ...

The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...

Partial heart transplants provide a range of lifesaving options for children with complex congenital heart conditions, and can lead to a domino effect of life-saving procedures.